Marrone Bio Innovations, Inc.Find Ratings Reports
MARRONE BIO INNOVTIONS's gross profit margin for the second quarter of its fiscal year 2021 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. MARRONE BIO INNOVTIONS has average liquidity. Currently, the Quick Ratio is 1.21 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 32.86% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||12.6||12.18|
|Net Income ($mil)||-3.04||-2.87|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||17.47||10.45|
|Total Assets ($mil)||85.62||78.4|
|Total Debt ($mil)||34.68||32.15|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||61.66||60.63|
|Return on Assets||-19.35||-46.42|
|Return on Equity||-47.78||-139.46|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||176.23||149.36|
|Div / share||0.0||0.0|
|Book value / share||0.2||0.17|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||702731.0||477498.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 4.73 indicates valuation on par with the S&P 500 average of 4.47 and a significant discount versus the subsector average of 7.68. The current price-to-sales ratio is well above the S&P 500 average and above the subsector average, indicating a premium. The valuation analysis reveals that, MARRONE BIO INNOVTIONS seems to be trading at a premium to investment alternatives.
|MBII NM||Peers 37.21||MBII NM||Peers 17.95|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
MBII's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MBII's P/CF is negative making the measure meaningless.
|MBII NM||Peers 25.89||MBII NA||Peers 1.74|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
MBII's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|MBII 4.73||Peers 7.68||MBII 62.07||Peers 133.91|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MBII is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, MBII is expected to significantly trail its peers on the basis of its earnings growth rate.
|MBII 4.08||Peers 3.77||MBII 13.22||Peers 14.24|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MBII is trading at a valuation on par with its subsector on this measurement.
Average. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share.
MBII is keeping pace with its peers on the basis of sales growth.